ArticleArchives of medical science : AMS2025
Antiviral flavonoids- and polyphenols-driven novel anti-HBV efficacy of
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quercetin potentially suppresses HBV activity through targeting the RIG-I/MAVS pathway.iScience · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antiviral natural products have shown great promise as alternatives to conventional therapies to address drug resistance in hepatitis B virus (HBV). The abundance of bioactive flavonoids and polyphenolic contents in leaves of Material and methods: The total ethanol extract of Results: All samples showed non-cytotoxicity except IP-EtAc, with mild toxicity at 200 μg/ml. Their anti-HBV assessment showed dose-dependent inhibitions of HBV antigens (HBsAg and HBeAg). At the selected optimal dose (50 μg/ml), while IP-Ext showed mild (HBsAg: 24.2% and HBeAg: 20.6%) and IP-Chl showed moderate (HBsAg: 42.3% and 40.1%) activity, IP-Hex (HBsAg: 55.6% and HBeAg: 52.4%) and IP-EtOH (HBsAg: 53.2% and HBeAg: 50.2%) exhibited high activity. HPLC revealed known anti-HBV flavonoids (rutin: 18.98, quercetin: 6.52 and kaempferol: 9.10 μg/g) and polyphenols (caffeic acid: 11.43 and chlorogenic acid: 3.22 μg/g) in the extract. Their (10 μg/ml, each) anti-HBV activities were: quercetin (HBsAg: 67.8% and HBeAg: 64.4%), kaempferol (HBsAg: 63.5% and HBeAg: 61.6%), chlorogenic acid (HBsAg: 55.2% and HBeAg: 53.8%), rutin (HBsAg: 51.2% and HBeAg: 48.4%) and caffeic acid (HBsAg: 42.2% and HBeAg: 39.5%). Notably, while our previous molecular docking had shown strong interactions of these flavonoids with HBV polymerase, here, we observed good binding affinity of the polyphenols with both drug-sensitive (wild-type) and drug-resistant (mutant) polymerases. Conclusions: This is the first study suggesting the anti-HBV therapeutic efficacy of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.